Technology | Virtual and Augmented Reality | June 10, 2019

Medivis SurgicalAR Gets FDA Clearance

Technology integrates augmented reality, artificial intelligence and computer vision to advance surgical visualization

Medivis SurgicalAR Gets FDA Clearance

June 10, 2019 — Medivis announced that its augmented reality (AR) technology platform for surgical applications, SurgicalAR, has received 510(k) clearance for clinical use in the operating room by the U.S. Food and Drug Administration (FDA). The New York City-based medical technology company will commence the immediate commercialization of the platform in the United States.

The enterprise SurgicalAR platform integrates the latest advancements in AR, artificial intelligence (AI) and computer vision to advance surgical visualization, thereby decreasing surgical complications and improving patient outcomes — all while lowering costs to the healthcare system.

This announcement comes on the heels of significant company momentum, including strategic partnerships with Verizon and Microsoft. Earlier this year, the company completed a seed round with $2.3M in funding, led by Initialized Capital. The company also recently released their AnatomyX platform for AR medical training.

Read the article "Medivis Unveils AnatomyX Augmented Reality Education Platform"

For more information: www.medivis.com

Related Content

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

The Caption Guidance software uses artificial intelligence to guide users to get optimal cardiac ultrasound images in a point of care ultrasound (POCUS) setting.

News | Artificial Intelligence | February 13, 2020
February 13, 2020 — The U.S.
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast

Mammograms of a 49-year-old woman with invasive lobular carcinoma on the right-side breast. A small mass with micro-calcifications on the right-side breast was detected correctly by AI with an abnormality score of 96%. This case was recalled by 7 out of 14 radiologists (4 breast radiologists and 3 general radiologists) initially (without AI) and all 14 radiologists recalled this case correctly with the assistance of AI.

News | Artificial Intelligence | February 11, 2020
February 11, 2020 — A new study, published in...
PaxeraHealth enterprise imaging, PACS, VNA solutions
News | Enterprise Imaging | February 11, 2020
February 11, 2020 — Enterprise Imaging developer PaxeraHealth
An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019.

An example of artificial intelligence (AI) being developed by Hitachi to automatically review and identify nodules on lung CT scans. This is part of a suite of AI apps Hitachi is developing. This example was being shown as a work in progress at RSNA 2019. Photo by Dave Fornell.

Feature | Artificial Intelligence | February 07, 2020 | Sanjay Parekh, Ph.D. 
February 7, 2020 – At the 2019 Radiological Society...
Sponsored Content | Videos | Artificial Intelligence | February 07, 2020
At RSNA19, GE Healthcare introduced its...
Sponsored Content | Videos | Artificial Intelligence | February 06, 2020
ProFound AI is an FDA-cleared artificial intelligence (AI) system for reading 3-D breast tomosynthesis images.
Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

News | Artificial Intelligence | February 04, 2020
February 4, 2020 — Since January 2020, the...